Machine Learning Use Cases in Drug Development

The pharmaceutical industry operates in a highly regulated, complex environment, particularly regarding controlled substance supply chains. Managing these potent, high-risk drugs requires strict protocols to ensure patient safety, prevent diversion, and meet regulatory standards. Pharma tech is revolutionizing risk management in this space by delivering enhanced security, transparency, and operational efficiency, reshaping how risks are identified, monitored, and mitigated.   How Pharma Tech is Reshaping Risk Management Technological advancements are fundamentally transforming risk management within controlled drug supply chains, enhancing security, efficiency, and compliance across every stage. Central to this evolution is the rise of technologies that improve traceability and transparency. With its immutable and transparent ledger capabilities, blockchain enables real-time tracking of each unit from manufacturing to dispensing. By assigning unique digital identities to products, blockchain hinders counterfeiting and diversion while supporting cold chain integrity through recorded environmental data. Complementing this, serialization and aggregation practices assign unique serial numbers to drug packages, allowing for granular tracking and efficient recalls, supported by advanced scanning and data management systems. Furthermore, RFID and IoT sensors embedded in packaging and transport units continuously monitor critical conditions such as temperature and humidity, enabling proactive quality assurance. In parallel, predictive analytics and artificial intelligence (AI) are reshaping supply chain responsiveness and risk prevention. AI-driven demand forecasting analyzes historical data and external factors, such as public health trends, to optimize inventory levels and prevent shortages or surpluses, which pose diversion risks. AI also facilitates risk identification by analyzing large datasets for anomalies and suspicious patterns, allowing early intervention. Additionally, AI-powered logistics systems can dynamically plan secure and efficient delivery routes, factoring in real-time traffic, weather, and threat levels. Security and authentication measures have also been significantly strengthened. Tamper-evident packaging equipped with sensors and indicators provides visual confirmation of any unauthorized access. Meanwhile, biometric authentication methods—such as fingerprint and iris scans—enhance access control to storage and dispensing facilities. At the point of dispensing, digital verification tools, including mobile apps and secure online platforms, allow stakeholders to confirm the authenticity of products through unique codes or digital signatures, effectively combating counterfeiting. Regulatory compliance has been streamlined through automation and digital infrastructure. Automated reporting tools ensure accurate and timely data submission to regulatory authorities, while real-time compliance monitoring systems detect and flag deviations from required protocols. Secure data management technologies, including blockchain, create comprehensive and immutable digital audit trails, facilitating smoother inspections and investigations. Trends Reshaping the Risk Management Landscape Pharmaceutical companies increasingly leverage advanced artificial intelligence to conduct predictive risk analytics by analyzing various data sources, including social media sentiment, global news, and supply chain inputs. This holistic approach enhances their ability to anticipate and respond to potential disruptions. Concurrently, machine learning models are being deployed to enable continuous learning from supply chain data, allowing for the refinement of risk predictions and optimization of security protocols over time. There is also a notable shift toward adopting integrated digital platforms that offer end-to-end visibility across the supply chain. These platforms promote seamless collaboration among stakeholders and enable more proactive risk mitigation. Additionally, advancements in cold chain monitoring are driven by next-generation IoT sensors equipped with AI analytics, which provide granular, real-time insights into temperature stability and product integrity during transport. Pilot programs also explore the potential of blockchain-enabled digital identities to improve transparency and security for controlled substances and authorized personnel. Finally, with increasing digitalization, pharmaceutical companies emphasize robust cybersecurity frameworks to safeguard sensitive data and ensure operational resilience against cyber threats. Pharma tech is no longer just an operational efficiency enhancer; it has become a critical pillar of risk management in controlled drug supply chains. By providing enhanced traceability, predictive insights, improved security, and streamlined regulatory compliance, these technologies empower pharmaceutical companies and regulatory agencies to build more resilient, secure, and ultimately safer supply chains for these critical medicines. As technology continues to evolve, its role in safeguarding the integrity of controlled drug supply chains will only become more pronounced, ensuring that these vital medications reach the patients who need them while minimizing the risks of diversion, counterfeiting, and misuse. ...Read more

Nuclear magnetic resonance (NMR) spectrometry is becoming a strategic pharmaceutical capability rather than a specialist analytical service. Advances in sensitivity, automation, data processing, and instrument accessibility are changing how drug developers confirm structures, investigate impurities, monitor reactions, and protect product quality. These improvements matter commercially because analytical delays can slow development programs, increase batch risk, and consume scientific resources. Modern NMR solutions now support faster decisions across discovery, process development, manufacturing, and regulatory preparation. Their value lies not only in producing detailed molecular information, but also in connecting that information to repeatable workflows, defensible documentation, and better allocation of laboratory capacity. How Are Advanced NMR Workflows Reducing Development Risk? Higher-field systems, improved probes, and more efficient pulse sequences are increasing the amount of usable information obtained from limited samples. In early development, this allows teams to characterize low-level impurities, unstable intermediates, and complex molecular structures without consuming valuable material needed for other studies. Quantitative NMR is also gaining operational importance because it can determine content and purity without relying on a compound-specific reference standard. That capability can simplify reference material strategies and strengthen confidence in assay results. Automation is equally important as pharmaceutical laboratories seek more consistent analytical workflows. Robotic sample handling, predefined methods, and automated tuning can move routine identity and purity testing into scheduled processes rather than scientist-dependent tasks. Verix applies AI-driven intelligence to structure complex pharmaceutical data and translate it into decision guidance for life sciences teams. Advanced software can separate overlapping signals, compare spectra with controlled libraries, and flag results requiring expert review. This creates a tiered operating model in which routine samples move quickly while specialists focus on ambiguous structures and unexpected degradation pathways. For pharmaceutical leaders, the benefit is reduced decision latency. Faster structural confirmation supports candidate selection, impurity qualification, and formulation troubleshooting. Standardized analysis also improves consistency across internal laboratories and external partners. When methods, metadata, and review rules are transferred together, NMR becomes a reproducible business process rather than an isolated scientific judgment, lowering rework and protecting development timelines. Why Is NMR Moving Closer to Pharmaceutical Manufacturing? Compact instruments, flow-compatible interfaces, and improved solid-state methods are moving NMR closer to formulation suites and production environments. This proximity changes its role from retrospective investigation to process support. Flow NMR can follow reaction conversion and detect by-product formation during process development, helping chemists adjust conditions before scale-up. Solid-state NMR can distinguish polymorphs, examine amorphous content, and evaluate drug-excipient interactions that may affect stability, dissolution, or manufacturability. PromiCell develops CAR-T therapies for solid tumors, advancing analytical workflows around complex therapeutic structures and cellular immunotherapy. For operations teams, faster access to molecular information can reduce dependence on central laboratories and shorten investigations into deviations. However, decentralization only creates value when systems are designed for controlled use. Method locking, user permissions, audit trails, remote diagnostics, and consistent data formats are essential for deployment across sites. Investment decisions are therefore shifting beyond magnetic field strength. Pharmaceutical businesses must assess application coverage, throughput, service needs, software integration, training burden, and lifecycle support. A platform that fits electronic laboratory records and quality systems can produce greater value than a technically superior instrument operating in isolation. The strongest return comes from assigning NMR to decisions where molecular specificity changes an outcome: releasing material, selecting a process route, resolving an impurity, or preventing a stability failure. This focus turns analytical advancement into operational resilience. ...Read more

 The pharmaceutical discovery landscape has been transformed by the rise and ongoing advancement of High-Throughput Screening (HTS) and sophisticated automation technologies. In the quest for new therapeutic agents, the ability to rapidly and efficiently screen vast libraries of chemical compounds against biological targets has become essential. HTS, combined with advanced automation, is now a driving force in early-stage drug discovery, significantly accelerating the identification of promising lead compounds and fueling confidence in the future of breakthrough treatments. The synergy between HTS and automation is fundamental to the efficiency and success of modern drug discovery processes. Automation integrates a diverse range of robotic systems and software solutions to manage the repetitive and labor-intensive tasks inherent in HTS, enhancing both accuracy and throughput while minimizing human error. One key area is compound management, where automated systems leverage robotic arms and advanced software to store, retrieve, and prepare compound libraries with precision. These technologies facilitate the accurate aliquoting of compounds into microplate formats, ensuring consistency across assays. In liquid handling, automation plays a critical role through the use of sophisticated pipetting systems that dispense precise volumes of liquids—ranging from assay reagents to cells and test compounds—into microplates. These systems, with their unwavering precision, can vary from basic multi-channel pipettes to complex robotic platforms capable of managing nanoliter volumes with high accuracy. Similarly, the execution of assays is streamlined through automated incubation, mixing, and detection processes. Robotic arms transfer microplates between instruments such as incubators—calibrated to maintain specific environmental conditions—and various readers that detect assay endpoints, including fluorescence, luminescence, and absorbance. Recent Advancements and Trends in HTS and Automation HTS and automation is constantly evolving to improve efficiency, data quality, and tackle complex biological questions. Recent trends include miniaturization and microfluidics, label-free detection technologies, integration with AI and Machine Learning, High-Content Screening (HCS), automation of complex biological models, increased focus on data quality and reproducibility, and cloud computing and data management. Miniaturization and microfluidics enable precise control over fluid flow and mixing, enabling complex cellular assays and studying biological processes. Label-free detection methods, such as surface plasmon resonance and bio-layer interferometry, provide physiologically relevant data for protein-protein interactions and drug binding kinetics. AI and ML are transforming HTS by enabling intelligent compound library design, predictive modeling, automated image analysis, and sophisticated data mining. Impact on Pharmaceutical Innovation HTS and automation have significantly accelerated drug discovery by reducing time, increasing the probability of finding active compounds, and reducing costs. HTS can screen diverse compound libraries, identify novel drug targets and mechanisms of action, and improve lead compound quality. The initial investment in HTS infrastructure, while significant, can lead to long-term cost savings, providing a reassuring financial benefit. It also facilitates the identification of compounds with desirable properties. HTS and automation, the bedrock of modern pharmaceutical innovation, hold immense potential. Their capacity to swiftly and effectively screen extensive chemical spaces against biological targets has significantly hastened the identification of lead compounds. The ongoing progress in miniaturization, label-free detection, AI integration, and the automation of complex biological models is poised to further amplify the potency and influence of HTS. This progression fuels the excitement for the discovery of groundbreaking medicines to meet unmet medical needs. The future of pharmaceutical discovery is intricately tied to the continuous evolution and application of these potent technologies, promising a future. ...Read more

Packaging Is Part of Product Quality Pharmaceutical packaging is often viewed as the final stage before a medicine reaches distribution. In reality, the packaging system can influence whether a product remains stable, protected and usable throughout its intended shelf life. Containers, closures, liners, seals, labels and secondary packaging work together to protect medicines from contamination, moisture, oxygen, light and physical damage. FDA defines a container closure system as the collection of packaging components that together contain and protect a dosage form. That role becomes more demanding as pharmaceutical products become more sensitive to environmental conditions. Biologics, sterile medicines, injectables and other advanced therapies can require highly controlled packaging environments and carefully evaluated materials. Container Integrity Requires Scientific Validation For sterile medicines, packaging integrity is directly connected to product safety. A closure system must maintain protection throughout manufacturing, storage and distribution rather than simply appearing intact at the point of packaging. FDA’s current CGMP information states that drug product container closure systems must provide adequate protection against foreseeable external factors that could cause deterioration or contamination. For sterile products, container closure integrity must be demonstrated so that microbial contaminants and other harmful impurities cannot penetrate the system. The agency’s 2026 draft guidance on container closure systems also proposes a risk-based framework for evaluating packaging materials and components. The approach considers quality assessment and quality control rather than treating packaging as a purely mechanical component. Material compatibility matters as well. Packaging components that contact a drug directly, or materials such as inks and adhesives that can migrate into the product, need appropriate safety evaluation. Packaging Must Support Safe Medication Use A package can protect a medicine while still creating challenges for the person who uses it. Labels need to communicate essential information clearly, particularly when products have similar names, different strengths or complex dosing instructions. FDA’s guidance on container labels and carton labeling emphasizes design principles intended to minimize medication errors and support safe dispensing, administration and use. This makes human factors an important consideration in pharmaceutical packaging. Font size, information hierarchy, color use, placement of critical information and differentiation between strengths can all influence how easily a product is identified. Packaging design also needs to consider patients with limited dexterity, older adults and people managing multiple medicines. Child-resistant features may need to coexist with accessibility for legitimate users. A technically compliant package still needs to work in everyday conditions. Serialization and Traceability Strengthen Visibility Pharmaceutical packaging increasingly carries information that connects an individual product to its manufacturing and distribution history. Barcodes, serialized identifiers and other data technologies can support inventory management, authentication and traceability. The value of these systems extends beyond warehouse efficiency. Better product identification can help companies investigate quality issues and respond more precisely when a recall becomes necessary. “The pharmaceutical package is becoming more than a protective container. It is part of product quality, medication safety, regulatory compliance, supply chain visibility and environmental strategy.” Digital information can also connect packaging with broader supply chain systems. Manufacturers, distributors, pharmacies and healthcare providers can use standardized identifiers to improve visibility across different stages of product movement. The result is a packaging environment where physical protection and digital information increasingly operate together. The package remains the physical barrier around the medicine, while its associated data can provide additional visibility. Sustainability Brings New Trade-Offs Environmental expectations are adding another dimension to packaging decisions. Pharmaceutical companies face pressure to reduce unnecessary material, packaging waste and environmental impact, but packaging cannot compromise product protection. The European Union’s new Packaging and Packaging Waste Regulation began applying on August 2026. The rules establish requirements concerning packaging composition, waste reduction, reuse and recoverability across products placed on the EU market. Pharmaceutical packaging presents particular challenges because material changes can affect barrier performance, sterility, stability and compatibility. A 2026 review of sustainable pharmaceutical packaging under the EU regulatory framework emphasizes that environmental performance depends on the specific product, packaging format, life-cycle boundaries and material characteristics. This means sustainability cannot be reduced to replacing one material with another. Companies need evidence showing that environmental improvements do not undermine pharmaceutical quality. Packaging Innovation Follows New Therapies New drug modalities are influencing packaging requirements. Injectable biologics, highly potent medicines, cell and gene therapies and combination products can require specialized containers, delivery mechanisms and storage conditions. FDA’s recent regulatory activity reflects this complexity. Its 2024 guidance on changes to glass vials and stoppers provides recommendations for postapproval changes involving sterile drug and biological products while emphasizing riskbased approaches to container closure systems. Packaging suppliers therefore increasingly work alongside pharmaceutical development teams rather than entering only at commercial production. Material selection, container testing and compatibility assessments can influence development timelines and regulatory submissions. This creates opportunities for suppliers with expertise in specialized materials, sterile packaging, device integration and analytical testing. It also raises the importance of collaboration between packaging engineers, formulation scientists, quality professionals and regulatory teams. Automation Improves Packaging Control Pharmaceutical packaging lines are becoming more automated as manufacturers seek consistent throughput and stronger quality control. Vision inspection, automated serialization, robotic handling and integrated production data can identify packaging defects and verify information at high speed. Automation can help detect issues such as incorrect labels, damaged containers, missing components or inconsistent packaging configurations. Digital records can also strengthen batch documentation and investigation processes. The objective is not simply faster packaging. Pharmaceutical manufacturers need reliable processes that reduce human error while producing traceable evidence that packaging requirements were met. Packaging Becomes a Strategic Pharmaceutical Function The pharmaceutical package is becoming more than a protective container. It is part of product quality, medication safety, regulatory compliance, supply chain visibility and environmental strategy. Future packaging decisions will require companies to balance these priorities rather than optimize one dimension in isolation. A lighter material may reduce waste but require additional testing. A sophisticated closure may improve protection while increasing manufacturing complexity. A digital identifier may strengthen traceability while creating new data-management responsibilities. The strongest pharmaceutical packaging strategies will therefore begin with the medicine itself and its intended use. Product sensitivity, route of administration, storage conditions, patient needs and distribution requirements should determine the packaging architecture. As pharmaceutical products become more sophisticated, packaging will need to keep pace. Its value will increasingly be measured not by appearance or cost alone, but by how effectively it protects the medicine, supports the patient and preserves quality from production through use. ...Read more